A Review of Accelerator-Produced Ga-68 with Solid Targets

Curr Radiopharm. 2021;14(4):315-324. doi: 10.2174/1874471013666201224113651.

Abstract

Gallium-68 is a positron-emitting nuclide that has recently achieved clinical acceptance as the diagnostic radionuclide in PET tracers used for theranostic studies of lutetium-177 labeled therapeutic drugs due to the ease of access provided by germanium-68/gallium-68 generators. An alternative method of production currently being explored uses accelerators to form gallium-68 directly. This review of gallium-68 production strategies discusses available accelerator targetry at a range of beam energies and intensities, the many radiochemical separation techniques available to isolate Ga-68 from irradiated targets, isotopically enriched target material recovery, and the implications of these techniques for downstream radiolabeling applications.

Keywords: Lu-177 labeled.; PET; Radiochemical; gallium-68; radiochemistry; therapeutic molecule.

Publication types

  • Review

MeSH terms

  • Cyclotrons
  • Gallium Radioisotopes / chemistry*
  • Lutetium / chemistry*
  • Positron-Emission Tomography
  • Precision Medicine
  • Radiochemistry / methods*
  • Radioisotopes / chemistry*
  • Radiopharmaceuticals / chemical synthesis*

Substances

  • Gallium Radioisotopes
  • Radioisotopes
  • Radiopharmaceuticals
  • Lutetium
  • Gallium-68
  • Lutetium-177